drugset
drugset / Trial / NCT06516887

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

NCT06516887 ↗

Phase 1/2 Terminated 4 enrolled The University of Texas Health Science Center at San Antonio National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase Ib/II, open-label, single institution dose-escalation, safety, pharmacokinetics, pharmacodynamic and efficacy study.

Timeline

Start
2024-12-27
Primary completion
2026-05-21
Completion
2026-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemcentinib Small molecule 50 mg Oral
Subject Bemcentinib Small molecule 75 mg Oral
Subject Bemcentinib Small molecule 100 mg Oral
Subject Bemcentinib Small molecule 125 mg Oral
Subject Pacritinib Small molecule 100 mg Oral
Subject Pacritinib Small molecule 200 mg Oral

Indications

lung adenocarcinoma